It's great to have options, and we have more options than ever before for managing heavily pretreated, relapsed/refractory multiple myeloma. The emergence of the new antibodies on the block—bispecifics—has led to notable improvements in outcomes for patients with advanced disease. But more options also means more decisions to be made about patient selection and sequencing. In this 60-minute session, two myeloma experts will discuss all of the practical considerations for integrating bispecific antibodies into the treatment of patients with heavily pretreated, relapsed myeloma. The faculty will both review the clinical evidence and guide you on what it means for your practice. Topics to be addressed include: how bispecific antibodies compare with CAR T-cell therapies, and when each should be used; recommended patient-centered strategies for preventing and managing treatment-related side effects; and how to facilitate collaborative care across clinics and providers to improve our patients' clinical outcomes and lives overall.

Come prepared for a lively session and Q&A on this important clinical topic.